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ABSTRACT
Sub-inhibitory concentrations of imipenem and
meropenem were evaluated for their ability to
induce morphological changes with six strains of
Acinetobacter baumannii isolated from patients
with nosocomial pneumonia. Three strains were
susceptible and three were resistant to carbapen-
ems. The strains were grown in the presence of 0
(controls), 0.25·, 0.5· and 1· the MIC of both
carbapenems for 4 h, and then examined after
Gram’s stain. Cells ‡ 3 lm in size (spheroplasts)
were considered to be altered. Both carbapenems
induced significant numbers of spheroplasts com-
pared to controls. Imipenem had more effect
against susceptible strains, while meropenem had
a greater effect against resistant strains.
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Various antimicrobial agents are known to retain
some activity at sub-MIC concentrations, causing
bacteria to undergo ultrastructural changes [1–3].
These changes promote opsonisation and phago-
cytosis [4–6], resulting in bacterial clearance by
the immune system, and explain, at least in part,
pharmacodynamic phenomena such as the post-
antibiotic effect [7]. Penicillins and cephalosporins
induce the formation of filamentous forms
because their primary target is penicillin-binding
protein 3 (PBP3) [1–3]. Several studies with
carbapenems have revealed the formation of
round cells (spheroplasts) with different species
of Gram-negative bacteria [8–11]. This differential
pattern has been explained by the affinity of
carbapenems for PBP2.
In the clinical setting, there are periods between
doses when the concentrations of antimicrobial
agents fall below the MICs for the infecting
bacteria; nevertheless most b-lactams will achieve
a bacteriological cure in many clinical scenarios,
provided that the concentration remains above the
MIC for ‡ 40% of the interval between doses;
indeed, this period may be even shorter (25–30%)
with carbapenems because of their prolonged
post-antibiotic effect [12]. Hence, the sub-MIC
actitivity (SMA) plays a significant role in antimi-
crobial therapy. This role may be of particular
relevance with multiresistant pathogens such as
Acinetobacter baumannii, which is now considered
to be one of the most important nosocomial
bacteria [13]. However, to our knowledge, there
are no data on the SMA of carbapenems against
A. baumannii. Therefore, the aim of the present
study was to assess the in-vitro SMA of imipenem
and meropenem against six clinical isolates of
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A. baumannii. Three strains were susceptible (SS)
and three were resistant (RS) to both carbapenems.
The strains were isolated from patients with
nosocomial pneumonia, and were identified by
the MicroScan system (Baxter Diagnostics, Deer-
field, IL, USA), the API20NE system (bioMe´rieux,
Marcy l’Etoile, France) and growth tests. MICs
were measured by the tube dilution method [14].
The SS were susceptible to imipenem (MICs of
0.38, 1 and 1 mg ⁄L, respectively) and meropenem
(MICs of 0.5, 0.75 and 1 mg ⁄L, respectively),
while the RS were resistant to both imipenem
(MICs of 16, 32 and 32 mg ⁄L, respectively) and
meropenem (MICs of 16, 16 and 32 mg ⁄L,
respectively). Antimicrobial agents were laborat-
ory standard powders (imipenem: Merck Sharp &
Dohme, Madrid, Spain; meropenem: AstraZene-
ca, Madrid, Spain).
Bacteria were inoculated into 20 mL of Muel-
ler–Hinton II Broth Cation-Adjusted (MHBCA;
Becton-Dickinson, Cockeysville, MD, USA) and
incubated at 37C for 4 h. A portion of the
suspension (106 CFU) was then added to 1 mL
of MHBCA containing concentrations of 0 (con-
trols), 0.25·, 0.5· and 1· the MIC of imipenem or
meropenem, and incubated at 37C for 4 h.
Following centrifugation (3000 g for 10 min), the
pellets were placed on calibrated glass slides and
examined following Gram’s stain (three slides for
every tube) under a light microscope with calib-
rated oculars (Nikon, Tokyo, Japan). One hun-
dred cells were examined on each slide.
Diplococci and bacilli < 3 lm in size were
considered to be normal, while forms ‡ 3 lm in
size were considered to be spheroplasts; forms
< 1 lm in size were not considered. Cell prepara-
tions were photographed with a Nikon FX-35 DX
camera fixed to the microscope, using 100ASA
film. Results were expressed as mean ± SD of the
altered forms on the nine slides examined for each
dilution and strain. For group comparisons, the
two-tailed t-test was used, with p-values < 0.05
considered to be significant.
The SMAs of imipenem and meropenem
against SS and RS are shown in Table 1 and
Fig. 1. Both carbapenems, at concentrations ran-
ging from 0.25· to 1· MIC, induced significant
numbers of spheroplasts in comparison with
controls. Imipenem showed higher activity than
meropenem against SS at 0.25· (89 ± 8 vs.
54 ± 15; p 0.016), 0.5· (92 ± 9 vs. 72 ± 7; p 0.003)
and 1· the MIC (93 ± 8 vs. 75 ± 7; p 0.003),
while meropenem was more active against RS
at 0.25· (85.6 ± 3.5 vs. 13.5 ± 4; p < 0.0001),
0.5· (95 ± 2 vs. 9 ± 3; p < 0.0001) and 1· the
MIC (97 ± 2.5 vs. 80 ± 5; p 0.01). This differential
activity has also been observed with Proteus
mirabilis [8], and it was hypothesised that it
could result from the different PBP affinities of
imipenem (which binds exclusively to PBP2) and
meropenem (which binds primarily to PBP2, but
also to PBP3). In the present study, both carbap-
enems induced substantial changes on the surface
of all A. baumannii strains tested, resulting in the
formation of spheroplasts > 3 lm in size. These
results agree with those reported with other
Gram-negative bacilli, and can therefore be con-
sidered to represent a specific characteristic of
carbapenems [8–11].
It has been suggested that the reduced release of
endotoxin following use of carbapenems, com-
pared to other b-lactams, results from this pattern
of SMA [10,11], as antimicrobial agents that induce
filamentation lead to a greater release of endotoxin
than those that induce spheroplasts [8–11]. The
resulting therapeutic benefits of this character-
istic have been demonstrated in experimental
infections. Thus, inmurinemodels of sepsis caused
Table 1. Sub-MIC activity of imipenem and meropenem against sensitive and resistant strains of Acinetobacter baumannii
Sensitive strains (n = 3) Resistant strains (n = 3)
Concentration
Altered forms
(mean ± SD) p Concentration
Altered forms
(mean ± SD) p
Imipenem
Control 0.1 ± 0.3 – Control 0 –
0.25 · MIC 89 ± 8 < 0.0001 0.25 · MIC 13.5 ± 4 0.0001
0.5 · MIC 92 ± 9 < 0.0001 0.5 · MIC 9 ± 3 < 0.035
1 · MIC 93 ± 8 < 0.0001 1 · MIC 80 ± 5 < 0.0001
Meropenem
Control 0.3 ± 0.5 – Control 0 –
0.25 · MIC 54 ± 15 < 0.0001 0.25 · MIC 85.6 ± 3.5 < 0.0001
0.5 · MIC 72 ± 7 < 0.0001 0.5 · MIC 95 ± 2 < 0.0001
1 · MIC 75 ± 7 < 0.0001 1 · MIC 97 ± 2.5 < 0.0001
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by Escherichia coli or Pseudomonas aeruginosa, imipe-
nem increased the lethal dose 50 (LD50)
8-fold, while ceftazidime increased the LD50 only
2–3-fold [15,16]. Similarly, with E. coli, it was
observed that imipenem induced a 6-fold greater
release of endotoxin than controls,while endotoxin
release with cefuroxime and aztreonam was 118·
and 222· the basal values, respectively [17].
Few studies have evaluated this issue in the
clinical setting. Prins et al. [18] compared the
clinical course and dynamics of inflammatory
parameters in patients with urological sepsis
treated with imipenem or ceftazidime; a shorter
duration of fever and lower urine and plasma
concentrations of endotoxin were observed in
patients treated with imipenem. In a retrospective
analysis of a clinical assay that evaluated adjuvant
interferon-c in patients with sepsis after severe
trauma, Mock et al. [19] observed higher mortality
(17% vs. 8%) in patients receiving PBP3-specific
antimicrobial agents (cephalosporins, aztreonam)
than in patients receiving antimicrobial agents
with no specificity against PBP3 (imipenem,
aminoglycosides and others). These experimental
and preliminary clinical studies point towards the
relevance of the SMA of antimicrobial agents in
the course of infections caused by Gram-negative
bacteria, but further prospective clinical studies
are needed to elucidate this issue.
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ABSTRACT
The effects of albumin and human serum on the
pharmacodynamics of faropenem were studied.
The protein binding of faropenem was 91–95%,
corresponding to the increase in MICs for Haemo-
philus influenzae in broth supplemented with
albumin. Time-kill experiments in albumin-con-
taining medium and in inactivated human serum
50% v ⁄ v showed that much higher drug concen-
trations were needed to achieve a bactericidal
effect than were needed in broth. Active human
serum alone exerted a strain-dependent bacteri-
cidal effect. It was concluded that it is the free
fraction of faropenem in serum that has antibac-
terial activity against H. influenzae.
Keywords Antimicrobial effect, faropenem, Haemo-
philus influenzae, pharmacodynamics, protein binding,
serum
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Faropenem is a synthetic antibiotic of the penem
group that is no longer under clinical develop-
ment, but which has antibacterial activity
against Gram-positive and Gram-negative bac-
teria, including strains producing ß-lactamase
[1,2]. The plasma protein binding of faropenem
is c. 90%, which affects its antibacterial activity
[3]. The aim of this study was to examine the
influence of human albumin and serum on the
pharmacodynamics of faropenem against
Haemophilus influenzae.
Ten H. influenzae strains were studied, inclu-
ding two b-lactamase-positive strains (LH 2803
and 405298), obtained from Glaxo SmithKline
Pharmaceuticals (Welwyn Garden City, UK), and
eight clinical isolates (four b-lactamase-positive)
obtained from the Department of Clinical Micro-
biology Laboratory, Uppsala University Hospital,
Sweden. Pooled human serum was obtained from
the same department and was heat-inactivated at
56C for 30 min. Mueller–Hinton broth (Difco
Laboratories, Detroit, MI, USA) supplemented
with haemin 30 mg ⁄L (Sigma, St Louis, MO,
USA) and IsoVitaleX (Becton Dickinson, Cockeys-
ville, MD, USA) 1% v ⁄ v was used throughout the
study.
Faropenem was provided by Bayer AG (Wup-
pertal, Germany) and dissolved in sterile distilled
water before each experiment. MICs were deter-
mined in broth with and without human albumin
(fraction V; Sigma) 40 g ⁄L by a macrodilution
technique with two-fold serial dilutions. Bacteria
from 6-h cultures were diluted to give a final
inoculum of 5 · 105 CFU ⁄mL and incubated at
35C in CO2 5% v ⁄ v for 20 h. The MIC was
defined as the lowest antibiotic concentration
with no visible growth.
Protein binding was determined by an ultrafil-
tration method in four different protein solutions:
human albumin 40 g ⁄L and 20 g ⁄L, and active
and inactivated human serum 50% v ⁄v. Plastic
tubes were saturated with CO2. Faropenem was
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